CliffBio
small molecule

ITRACONAZOLE

ITRACONAZOLE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameITRACONAZOLE
Active ingredientITRACONAZOLE
Strength10MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2019
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.